Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com -- Genprex (NASDAQ:GNPX) stock jumped 21% following the presentation of positive preclinical data for its Reqorsa Gene Therapy in treating ALK-positive non-small cell lung cancer.
The data, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, showed Reqorsa’s effectiveness both as a standalone treatment and when combined with other therapies. Research collaborators from the University of Michigan Rogel Cancer Center demonstrated that Reqorsa can overexpress the tumor suppressor gene TUSC2 in cancer cell lines and patient-derived organoids.
The preclinical studies revealed that Reqorsa induced apoptosis (cell death) in ALK-positive NSCLC cells, including those resistant to the drug alectinib. When combined with alectinib, Reqorsa further increased apoptosis and improved survival in mouse models compared to control groups.
"The preclinical data presented at AACR-NCI-EORTC reinforces our oncology program strategy that reintroduces tumor suppressor genes to target cancer cells," said Ryan Confer, President and CEO of Genprex. "These data also add to the existing preclinical data showing that REQORSA has significant activity on its own as well as when combined with other therapies."
ALK-EML4 rearrangements occur in approximately 4% of all patients with NSCLC. The company indicated these results could open a pathway for potential future clinical trials in ALK-positive lung cancer patients.
Reqorsa consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles, designed to deliver the functioning TUSC2 gene to cancer cells while minimizing uptake by normal tissue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.